Suppr超能文献

甘精胰岛素300单位/毫升:糖尿病管理相关医护人员指南。

Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes.

作者信息

Strong Jodi, Kruger Davida, Novak Lucia

机构信息

a Ministry Medical Group , Stevens Point , WI , USA.

b Henry Ford Medical Center, Division of Endocrinology, Diabetes, Bone and Mineral Disorders , Detroit , MI , USA.

出版信息

Curr Med Res Opin. 2017 Apr;33(4):785-793. doi: 10.1080/03007995.2017.1288614. Epub 2017 Mar 7.

Abstract

UNLABELLED

Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Glucose control: Recently approved in the United States and in Europe for use in type 1 and type 2 diabetes, Gla-300 has a more constant and evenly distributed glucose-lowering effect compared with Gla-100, with a duration of action beyond 24 hours and lower within-day and between-day intra-individual variability in blood glucose levels. These benefits translate into predictable and sustained glucose control from a once-daily injection, with potential for fewer hypoglycemia episodes and less weight gain.

CASE STUDIES

Case studies are presented to highlight the potential clinical benefits and considerations associated with initiating treatment with Gla-300 in people with type 1 and type 2 diabetes.

摘要

未标注

甘精胰岛素300单位/毫升:甘精胰岛素300单位/毫升(Gla-300)是甘精胰岛素的一种制剂,其在三分之一的甘精胰岛素100单位/毫升(Gla-100)注射体积中输送相同数量的胰岛素单位。血糖控制:Gla-300最近在美国和欧洲被批准用于1型和2型糖尿病,与Gla-100相比,它具有更持续且分布更均匀的降糖效果,作用持续时间超过24小时,日内和日间个体内血糖水平变异性更低。这些益处转化为每日一次注射可实现可预测且持续的血糖控制,低血糖发作次数可能更少且体重增加更少。

病例研究

呈现病例研究以突出在1型和2型糖尿病患者中起始使用Gla-300治疗相关的潜在临床益处和注意事项。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验